(Q34127439)

31 July 2017

1 reference

title

Delavirdine: a review of its use in HIV infection (English)

1 reference

31 July 2017

L J Scott

1

1 reference

PubMed ID

11152019

31 July 2017

C M Perry

series ordinal

2

1 reference

31 July 2017

1 December 2000

1 reference

31 July 2017

1 reference

31 July 2017

60

1 reference

31 July 2017

6

1 reference

31 July 2017

1411-1444

1 reference

https://scigraph.springernature.com/pub.10.2165/00003495-200060060-00013

31 July 2017

0 references

cites work

Locations of anti-AIDS drug binding sites and resistance mutations in the three-dimensional structure of HIV-1 reverse transcriptase. Implications for mechanisms of drug inhibition and resistance

1 reference

12 December 2020

Interferon alpha in the treatment of AIDS-related Kaposi's sarcoma

1 reference

12 December 2020

The role of alpha-interferon in patients with human immunodeficiency virus infection

1 reference

12 December 2020

Changing patterns of mortality across Europe in patients infected with HIV-1. EuroSIDA Study Group.

1 reference

12 December 2020

Microsomal metabolism of delavirdine: evidence for mechanism-based inactivation of human cytochrome P450 3A

1 reference

12 December 2020

Randomized, controlled phase I/II, trial of combination therapy with delavirdine (U-90152S) and conventional nucleosides in human immunodeficiency virus type 1-infected patients.

1 reference

12 December 2020

A mutation in reverse transcriptase of bis(heteroaryl)piperazine-resistant human immunodeficiency virus type 1 that confers increased sensitivity to other nonnucleoside inhibitors

1 reference

12 December 2020

ACTG 260: a randomized, phase I-II, dose-ranging trial of the anti-human immunodeficiency virus activity of delavirdine monotherapy. The AIDS Clinical Trials Group Protocol 260 Team

1 reference

12 December 2020

The use of combination antiretroviral therapy in HIV-infected patients

1 reference

12 December 2020

Suppression of plasma viral load below 20 copies/ml is required to achieve a long-term response to therapy

1 reference

12 December 2020

A novel dipyridodiazepinone inhibitor of HIV-1 reverse transcriptase acts through a nonsubstrate binding site

1 reference

12 December 2020

Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy

1 reference

12 December 2020

Efficacy and safety of combination therapy with delavirdine and zidovudine: a European/Australian phase II trial

1 reference

12 December 2020

Nevirapine: a review of its use in the prevention and treatment of paediatric HIV infection

1 reference

12 December 2020

Anti-human immunodeficiency virus type 1 activities of U-90152 and U-75875 in human brain cell cultures

1 reference

12 December 2020

1998 revision to the British HIV Association guidelines for antiretroviral treatment of HIV seropositive individuals. BHIVA Guidelines Writing Committee

1 reference

12 December 2020

Unique features in the structure of the complex between HIV-1 reverse transcriptase and the bis(heteroaryl)piperazine (BHAP) U-90152 explain resistance mutations for this nonnucleoside inhibitor

1 reference

12 December 2020

Delavirdine susceptibilities and associated reverse transcriptase mutations in human immunodeficiency virus type 1 isolates from patients in a phase I/II trial of delavirdine monotherapy (ACTG 260)

1 reference

12 December 2020

Characterization of the binding site for nevirapine (BI-RG-587), a nonnucleoside inhibitor of human immunodeficiency virus type-1 reverse transcriptase

1 reference

12 December 2020

Bisheteroarylpiperazine reverse transcriptase inhibitor in combination with 3'-azido-3'-deoxythymidine or 2',3'-dideoxycytidine synergistically inhibits human immunodeficiency virus type 1 replication in vitro

1 reference

12 December 2020

Structure of HIV-1 RT/TIBO R 86183 complex reveals similarity in the binding of diverse nonnucleoside inhibitors

1 reference

12 December 2020

Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators

1 reference

12 December 2020

In vitro protein-binding characteristics of delavirdine and its N-dealkylated metabolite

1 reference

12 December 2020

Simple, rapid and sensitive high-performance liquid chromatographic determination of delavirdine and its N-desisopropyl metabolite in human plasma

1 reference

12 December 2020

The binding of a novel bisheteroarylpiperazine mediates inhibition of human immunodeficiency virus type 1 reverse transcriptase

1 reference

12 December 2020

Recovery of replication-competent HIV despite prolonged suppression of plasma viremia

1 reference

12 December 2020

Pharmacokinetic study of the interaction between rifampin and delavirdine mesylate

1 reference

12 December 2020

Choosing the best initial therapy for HIV-1 infection

1 reference

12 December 2020

HIV disease treatment in the era of HAART.

1 reference

12 December 2020

Rate of HIV-1 RNA rebound upon stopping antiretroviral therapy.

1 reference

12 December 2020

The quasispecies (extremely heterogeneous) nature of viral RNA genome populations: biological relevance--a review

1 reference

12 December 2020

Efficacy and safety of delavirdine mesylate with zidovudine and didanosine compared with two-drug combinations of these agents in persons with HIV disease with CD4 counts of 100 to 500 cells/mm3 (ACTG 261). ACTG 261 Team

1 reference

12 December 2020

Triple nucleoside analogue antiretroviral therapy: expanding the treatment approaches for management of HIV infection

1 reference

12 December 2020

Kinetic studies with the non-nucleoside human immunodeficiency virus type-1 reverse transcriptase inhibitor U-90152E.

1 reference

12 December 2020

HIV population dynamics in vivo: implications for genetic variation, pathogenesis, and therapy

1 reference

12 December 2020

The role of non-nucleoside reverse transcriptase inhibitors (NNRTIs) in the therapy of HIV-1 infection.

1 reference

12 December 2020

U-90152, a potent inhibitor of human immunodeficiency virus type 1 replication

1 reference

12 December 2020

Mortality impact of the AIDS epidemic: evidence from community studies in less developed countries.

1 reference

12 December 2020

Antiretroviral therapy in adults: updated recommendations of the International AIDS Society-USA Panel

1 reference

12 December 2020

Prevalence and incidence of resistance to zidovudine and other antiretroviral drugs

1 reference

12 December 2020

When do HIV-infected persons start with antiretroviral therapy? A retrospective analysis of patients' monitoring and treatment status in general practice, as compared with the 1991 Dutch HIV treatment guidelines

1 reference

12 December 2020

Pharmacokinetic study of the interaction between rifabutin and delavirdine mesylate in HIV-1 infected patients

1 reference

12 December 2020

Metabolism of the HIV-1 reverse transcriptase inhibitor delavirdine in mice.

1 reference

12 December 2020

Steady-state pharmacokinetics of delavirdine in HIV-positive patients: effect on erythromycin breath test

1 reference

12 December 2020

HIV-1 chemotherapy and drug resistance

1 reference

12 December 2020

Resistance to non-nucleoside inhibitors of HIV-1 reverse transcriptase

1 reference

12 December 2020

Pharmacokinetic drug-drug interaction study of delavirdine and indinavir in healthy volunteers

1 reference

12 December 2020

Metabolism of delavirdine, a human immunodeficiency virus type-1 reverse transcriptase inhibitor, by microsomal cytochrome P450 in humans, rats, and other species: probable involvement of CYP2D6 and CYP3A.

1 reference

12 December 2020

The AIDS epidemic--considerations for the 21st century

1 reference

12 December 2020

Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy

1 reference

12 December 2020

Inhibition of human immunodeficiency virus type 1 infection in vitro by combination of delavirdine, zidovudine and didanosine

1 reference

12 December 2020

Human immunodeficiency virus protease inhibitors

1 reference

12 December 2020

Attaining higher goals in HIV treatment: the central importance of adherence

1 reference

12 December 2020

Pharmacokinetic interaction of amprenavir in combination with efavirenz or delavirdine in HIV-infected children.

1 reference

12 December 2020

Rapid quantification of delavirdine, a novel non-nucleoside reverse transcriptase inhibitor, in human plasma using isocratic reversed-phase high-performance liquid chromatography with fluorescence detection

1 reference

12 December 2020

In vitro inhibition of human immunodeficiency virus type 1 by a combination of delavirdine (U-90152) with protease inhibitor U-75875 or interferon-alpha

1 reference

12 December 2020

Mechanism of inhibition of HIV-1 reverse transcriptase by non-nucleoside inhibitors

1 reference

12 December 2020

Mechanism of resistance to U-90152S and sensitization to L-697,661 by a proline to leucine change at residue 236 of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase

1 reference

12 December 2020

Mechanism of inhibition of HIV-1 reverse transcriptase by nonnucleoside inhibitors.

1 reference

12 December 2020

Alterations in gastric acidity in patients infected with human immunodeficiency virus

1 reference

12 December 2020

Effect of fluconazole on the steady-state pharmacokinetics of delavirdine in human immunodeficiency virus-positive patients

1 reference

12 December 2020

Activity of non-nucleoside reverse transcriptase inhibitors against HIV-2 and SIV

1 reference

12 December 2020

Continued lamivudine versus delavirdine in combination with indinavir and zidovudine or stavudine in lamivudine-experienced patients: results of Adult AIDS Clinical Trials Group protocol 370.

1 reference

12 December 2020

Combination antiretroviral therapy and recent declines in AIDS incidence and mortality

1 reference

12 December 2020

A risk-benefit assessment of HIV protease inhibitors

1 reference

12 December 2020

The P236L delavirdine-resistant human immunodeficiency virus type 1 mutant is replication defective and demonstrates alterations in both RNA 5'-end- and DNA 3'-end-directed RNase H activities

1 reference

12 December 2020

Metabolism of the human immunodeficiency virus type 1 reverse transcriptase inhibitor delavirdine in rats.

1 reference

12 December 2020

Antiretroviral drug resistance testing in adult HIV-1 infection: recommendations of an International AIDS Society-USA Panel.

1 reference

12 December 2020

Identification of the metabolites of the HIV-1 reverse transcriptase inhibitor delavirdine in monkeys

1 reference

12 December 2020

Overview of HIV infection.

1 reference

12 December 2020

Predictors of optimal virological response to potent antiretroviral therapy

1 reference

12 December 2020

Effects of non-nucleoside inhibitors of human immunodeficiency virus type 1 in cell-free recombinant reverse transcriptase assays

1 reference

12 December 2020

Drug interactions of HIV protease inhibitors

1 reference

12 December 2020

Crystal structure at 3.5 A resolution of HIV-1 reverse transcriptase complexed with an inhibitor

1 reference

12 December 2020

Delavirdine mesylate, a potent non-nucleoside HIV-1 reverse transcriptase inhibitor.

1 reference

12 December 2020

Single-dose pharmacokinetics of delavirdine mesylate and didanosine in patients with human immunodeficiency virus infection

1 reference

12 December 2020

10.2165/00003495-200060060-00013

Identifiers

DOI

1 reference

PubMed ID

11152019

Dimensions Publication ID

31 July 2017

0 references

1 reference

PubMed ID

11152019